Announced updated STS101 development plan featuring a new Phase 3 efficacy trial scheduled to begin enrollment mid-2021 with topline results...
IND accepted for VOR33, Vor’s lead eHSC product candidate for treatment of AML Completed initial public offering raising $203.4 million...
WATERTOWN, Mass., March 25, 2021 (GLOBE NEWSWIRE) -- Since the start of the coronavirus pandemic more than a year ago,...
Ji’an, Jiangxi, China, March 25, 2021 (GLOBE NEWSWIRE) -- Universe Pharmaceuticals INC (the “Company”) (Nasdaq: UPC), a pharmaceutical producer and...
SAN DIEGO, March 25, 2021 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced...
Actively recruiting patients in two global, clinical studies evaluating seladelpar in primary biliary cholangitis (PBC): RESPONSE, a 52-week, randomized, placebo-controlled,...
WALTHAM, Mass., March 25, 2021 (GLOBE NEWSWIRE) -- EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG), (“EyeGate” or the “Company”), a clinical-stage company...
MINNEAPOLIS, March 25, 2021 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage biopharmaceutical company developing disruptive therapeutics...
NEWTON, Mass., March 25, 2021 (GLOBE NEWSWIRE) -- IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF MASSACHUSETTS DAVID...
Progressed lead programs VRDN-001 and VRDN-002 towards clinical trials in Thyroid Eye Disease (TED); both IND filings expected by the...
Achieved Full Year 2020 Total Revenues of $42.2 Million, a 44% Increase Over Full Year 2019 Accelerated ADMA BioCenters Plasma...
Announces MydCombi expected PDUFA date of October 28, 2021 Completes patient enrollment in Phase 3 VISION-1 study evaluating MicroLine for...
Expects to Complete Enrollment and Report Top-Line Data of the Phase 2b/3 PRISM Trial in Second Half of 2021 Cash...
SAN DIEGO, March 25, 2021 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ: HSTO), a clinical-stage therapeutics company focused on developing potential...
SAINT-LAURENT, Quebec, March 25, 2021 (GLOBE NEWSWIRE) -- IntelGenx Technologies Corp. (TSX V:IGX)(OTCQX:IGXT) (the "Company" or "IntelGenx") today reported financial results...
Full Year Revenue Increase of 15% Management to Host Conference Call Today at 5:00 pm ET HIGHLANDS RANCH, Colo., March...
DURHAM, N.C., March 25, 2021 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in...
Advanced two programs, RLY-1971 and RLY-4008, into clinical development, and on track to initiate IND enabling studies with PI3Kα mutant...
Company announcement – No. 17 / 2021Zealand Pharma to participate in upcoming investor conferencesCopenhagen, DK and Boston, MA, U.S. March...
Continued progress in dosing of patients in clinical trial of NKX101, investigational CAR NK cell therapy engineered with NKG2D receptor,...